SWX:BAER
SWX:BAERCapital Markets

Is Now the Right Time to Consider Julius Bär After Recent 8.7% Monthly Slide?

If you are standing at the crossroads of whether to buy, sell, or hold Julius Bär Gruppe, you are not alone. Investors have watched the stock make some strong moves in recent years, and there is a real question about whether the current price offers genuine value or a reason for caution. The stock’s journey has been anything but dull: while the past week and month have brought noticeable dips (down 5.7% and 8.7%, respectively), anyone who zooms out will see that the last twelve months...
SWX:VBSN
SWX:VBSNMedical Equipment

European Dividend Stocks To Consider In September 2025

As European markets navigate a landscape of mixed economic signals and monetary policy decisions, the pan-European STOXX Europe 600 Index recently ended the week slightly lower. In this environment, dividend stocks may offer investors a potential source of steady income, especially as central banks maintain cautious stances on interest rates.
SWX:MOBN
SWX:MOBNReal Estate

How Mobimo’s Meggen Site Acquisition (SWX:MOBN) Is Shaping Its Central Switzerland Investment Story

On September 1, 2025, Mobimo Holding AG acquired a 12,000 m² site in Meggen near Lake Lucerne, with plans to develop approximately 70 condominium units valued at CHF 120 million. The development taps into one of Central Switzerland’s most sought-after residential markets, further building on Mobimo’s track record in the region. We’ll explore how this significant pipeline expansion in an attractive location could shape Mobimo’s broader investment narrative. These 9 companies survived and...
SWX:MOVE
SWX:MOVEMedical Equipment

Does Medacta Group’s Growth Guidance and Innovation Push Strengthen Analyst Confidence in SWX:MOVE?

Medacta Group SA recently reported strong half-year earnings, with sales reaching €344.14 million and net income rising to €60.04 million, while confirming 2025 guidance targeting 16% to 18% revenue growth in constant currency. Alongside these financial results, the company continued to expand its Personalized Sports Medicine Portfolio, launching the QuickStitch device at a major industry congress, highlighting ongoing investment in innovation and physician education. We'll examine how...